Document is current

Article History

Received: 12 May 2024

Accepted: 4 December 2024

First Online: 16 January 2025

Competing interests

: G.R. reports disclosures related to consulting fees (Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Stemline), payment/honoraria (Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche, Seagen, Stemline, BMS) and travel/accommodations/expenses (Amgen, Daiichi Sankyo, Eli Lilly, Gilead, Merck, Pfizer, Roche). D.E. reports disclosures related to consulting fees (AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Menarini, Novartis, Pfizer, Roche, Seagen, Sirius Medical), payment/honoraria (AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen, Sirius Medical), expert testimony (AstraZeneca, Daiichi Sankyo, Gilead, Lilly), travel/accommodations/expenses (AstraZeneca, Daiichi Sankyo, Pfizer), an advisory role (AstraZeneca, Daiichi Sankyo) and receipt of equipment/materials from Sirius Medical. R.B. reports disclosures related to grants/contracts (Daiichi Sankyo), consulting fees (AstraZeneca, Daiichi, Eisai, Eli Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Seagen, Stemline), payment/honoraria (AstraZeneca, BMS, Daiichi, Eisai, Eli Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Seagen), travel/accommodations/expenses (Daiichi, MSD, Pfizer) and an advisory role (WSG). C.A.S. reports disclosures related to support for the paper (Roche), grants/contracts (Roche), payment/honoraria (Roche) and travel/accommodations/expenses (Roche). A.P. reports disclosures related to payments for an advisory role (Novartis, Amgen, Celgene/BMS, Sandoz, Janssen, AstraZeneca, Abbvie, Takeda, Sanofi, Kite–Gilead, Roche, Pfizer, Seagen, Daiichi Sankyo) and travel/accommodations/expenses (Roche, Gilead, Daiichi Sankyo, Janssen, Eli Lilly, Pierre Fabre). M.B. reports disclosures related to grants/contracts (Amgen, AstraZeneca, Cepheid, Daiichi Sankyo, Gilead, MSD, Novartis, Seagen), consulting fees (Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Samsung, Gilead, Seagen), payment/honoraria (Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Seagen, Gilead), travel/accommodations/expenses (AstraZeneca, Daiichi Sankyo, MSD, Roche), an advisory role (Pfizer, GBG, Novartis) and a leadership/fiduciary role (OeGHO, ABCSG). E.P. reports disclosures related to support for the paper (Roche), payment/honoraria (Roche) and an advisory role (Roche). C.F.S. reports disclosures related to grants/contracts (Amgen, Roche, AstraZeneca, Daiichi), consulting fees (AstraZeneca, Novartis), payment/honoraria (Novartis, AstraZeneca, Daiichi, Seagen, Amgen), travel/accommodations/expenses (Daiichi) and an advisory role (WSG). S.P.G. reports disclosures related to consulting fees (Roche), payment/honoraria (Roche), travel/accommodations/expenses (Roche) and an advisory role (Roche). M.K. reports disclosures related to an advisory role (WSG). D.H. reports disclosures related to support for the paper (Roche). L.S. reports disclosures related to support for the paper (Roche). Z.B.-H. reports disclosures related to consulting fees (AstraZeneca, Menarini Stemline, MSD) and payment/honoraria (AstraZeneca, MSD). M. Gili reports disclosures related to support for the paper (Roche). L.W. reports disclosures related to payment/honoraria (Roche Austria) and travel/accommodations/expenses (Roche Austria). M.M. reports disclosures related to consulting fees (Roche, Eli Lilly, Novartis, AstraZeneca, Daiichi Sankyo, Pfizer, MSD), payment/honoraria (MedMedia, Roche, Eli Lilly, Novartis, AstraZeneca, Daiichi Sankyo, Pfizer, MS), travel/accommodations/expenses (Amgen, Roche, Novartis, MSD, Pierre Fabre, Daiichi Sankyo, Eisai), an advisory role (Eli Lilly, Novartis, AstraZeneca, Daiichi Sankyo, Pfizer, MSD) and receipt of equipment/materials (AstraZeneca, Astellas). B.S. reports disclosures related to travel/accommodations/expenses (Roche Austria). R.P. reports disclosures related to payment/honoraria (Myriad, Roche, Amgen, AstraZeneca, Novartis, Daiichi Sankyo, Pfizer, MedMedia), travel/accommodations/expenses (Pfizer, Novartis) and an advisory role (Novartis, Pfizer, AstraZeneca, Roche). M. Gnant reports disclosures related to consulting fees (AstraZeneca, Daiichi Sankyo, Menarini Stemline, MSD, Novartis), payment/honoraria (Amgen, Daiichi Sankyo, Eli Lilly, EPG Health (IQVIA), Menarini Stemline, Novartis, Pierre Fabre, Veracyte), expert testimony payment (Eli Lilly), travel/accommodations/expenses (Eli Lilly, Menarini Stemline, Novartis, Pierre Fabre) and an advisory role (AstraZeneca, Eli Lilly); an immediate family member is employed by Sandoz. R.G. reports disclosures related to consulting fees (Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Amgen, Merck, Gilead, Daiichi Sankyo, Sanofi), payment/honoraria (Celgene, Roche, Merck, Takeda, AstraZeneca, Novartis, Amgen, BMS, MSD, Sandoz, Abbvie, Gilead, Daiichi Sankyo, Sanofi), travel/accommodations/expenses (Roche, Amgen, Janssen, AstraZeneca, Novartis, MSD, Celgene, Gilead, BMS, Abbvie, Daiichi Sankyo), an advisory role (Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Amgen, Merck, Gilead, Daiichi Sankyo, Sanofi) and stock/stock options (Novo Nordisk, Lilly). The other authors declare no competing interests.